COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities

Bonnie Ky; Douglas L. Mann

doi:10.1016/j.jacbts.2020.04.003

COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities

Bonnie Ky, Douglas L. Mann

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, the authors provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.

Original language	English
Pages (from-to)	501-517
Number of pages	17
Journal	JACC: Basic to Translational Science
Volume	5
Issue number	5
DOIs	https://doi.org/10.1016/j.jacbts.2020.04.003
State	Published - May 2020

Keywords

ACE2
COVID-19
SARS-CoV-2
clinical trials
renin angiotensin system

Access to Document

10.1016/j.jacbts.2020.04.003

Cite this

@article{10fc049644214cd1916a14fdf4fcf2e5,

title = "COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities",

abstract = "The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, the authors provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.",

keywords = "ACE2, COVID-19, SARS-CoV-2, clinical trials, renin angiotensin system",

author = "Bonnie Ky and Mann, {Douglas L.}",

note = "Funding Information: This work was supported by grants from the National Institutes of Health (R21HL141802, R34HL146927, and R01HL118018 to Dr. Ky; and R01HL107594 and U10 HL110309 to Dr. Mann) and the American Heart Association (TPA34910059 to Dr. Ky). This paper will co-publish in JACC: Basic to Translational Science and JACC: CardioOncology. Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = may,

doi = "10.1016/j.jacbts.2020.04.003",

language = "English",

volume = "5",

pages = "501--517",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

number = "5",

}

TY - JOUR

T1 - COVID-19 Clinical Trials

T2 - A Primer for the Cardiovascular and Cardio-Oncology Communities

AU - Ky, Bonnie

AU - Mann, Douglas L.

N1 - Funding Information: This work was supported by grants from the National Institutes of Health (R21HL141802, R34HL146927, and R01HL118018 to Dr. Ky; and R01HL107594 and U10 HL110309 to Dr. Mann) and the American Heart Association (TPA34910059 to Dr. Ky). This paper will co-publish in JACC: Basic to Translational Science and JACC: CardioOncology. Publisher Copyright: © 2020 The Authors

PY - 2020/5

Y1 - 2020/5

N2 - The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, the authors provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.

AB - The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, the authors provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.

KW - ACE2

KW - COVID-19

KW - SARS-CoV-2

KW - clinical trials

KW - renin angiotensin system

UR - http://www.scopus.com/inward/record.url?scp=85084405891&partnerID=8YFLogxK

U2 - 10.1016/j.jacbts.2020.04.003

DO - 10.1016/j.jacbts.2020.04.003

M3 - Review article

C2 - 32309679

AN - SCOPUS:85084405891

SN - 2452-302X

VL - 5

SP - 501

EP - 517

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 5

ER -

COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this